Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  5.00 0.59% 850.00 840.00 860.00 850.00 836.00 845.00 110,262 08:35:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 632

Maxcyte Share Discussion Threads

Showing 276 to 298 of 650 messages
Chat Pages: Latest  14  13  12  11  10  9  8  7  6  5  4  3  Older
DateSubjectAuthorDiscuss
05/12/2020
18:38
hxxps://www.globenewswire.com/news-release/2020/12/05/2140152/0/en/CRISPR-Therapeutics-and-Vertex-Present-New-Data-for-Investigational-CRISPR-Cas9-Gene-Editing-Therapy-CTX001-at-American-Society-of-Hematology-Annual-Meeting-and-Exposition-Together.html Good news for maxcyte
nimbo1
02/12/2020
23:32
Good twitter thread on MXCT hTTps://threadreaderapp.com/thread/1334258158609502210.html
homebrewruss
02/12/2020
09:23
No online quote to buy at the moment.
bamboo2
02/12/2020
09:13
The 'no-reason' breakaway gap at 370-374 is probably going to fill. This gap was the result of a tip somewhere I think. It is an area of historical support and will hold imo. Possible turn shows on the chart 2-3/12/2020
bamboo2
02/12/2020
08:37
Always a slight concern, when one of your holdings seems to tumble on nothing known in the market......
assagai
23/11/2020
11:52
Encouraging progress. https://www.dailymail.co.uk/news/article-8975517/Israeli-scientists-kill-cancer-cells-ground-breaking-DNA-altering-treatment-CRISPR.html
acuere
23/11/2020
09:57
https://www.dailymail.co.uk/news/article-8975517/Israeli-scientists-kill-cancer-cells-ground-breaking-DNA-altering-treatment-CRISPR.html
jones1961
18/11/2020
08:28
There was a CARMA Q&A entitled, "MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR during SITC's Poster Symposium with a live Q&A on Thursday, November 12. I haven't seen a transcript of this. The Stifel presentation slides (17th Nov) have now been posted on the MXCT Investor site. I note a slight change in the wording on a CARMA deal ''Management exploring independent investment to drive the CARMA opportunity, following recent positive progress, targeting to be self funded by end of 2020''. Targeting would have been better wording to use from the start, these deals are complex. ''Positive progress'' is good &, in any event IMO, some slippage in timing, as long as not excessive, doesn't change the equity story. To be noted though.
rgmgo
13/11/2020
14:19
Edward , what presentation? I didn't think it was until 17th and then 19th? Thanks, if you can explain.
assagai
13/11/2020
14:18
not yet but I hope to when they appear on the website. Sounds exciting and importantly sounds like something the Americans should value!
nimbo1
13/11/2020
13:59
anyone else listen in ? presentation done as Carma not maxcyte so underlined the split is likely. got to hope external funding is soon.the fact that it mentioned effective and long term antitumour immune responses has to be bloody exciting doesn't it?!
edwardt
11/11/2020
15:36
Interesting, thanks for flagging - $1 billion market cap! Company has been around many years but maxcyte has a c.90% market share I believe in their niche...so whatever they are doing it doesn't appear to be competing well. However in time I would expect some form of proper competition to maxcyte as the market looks attractive!
nimbo1
11/11/2020
11:57
I share the warm feelings towards the MXCT investment proposition outlined by the majority on this site but it is clearly worth keeping an eye on competitive developments. MXCT has enormous advantages as a technology pioneer, and from deep customer relationships, and assuming the industry successfully scales there will probably be space for Precigen (see press release below) and others. For general interest. hxxps://investors.precigen.com/news-releases/news-release-details/precigens-ultraporatortm-receives-fda-clearance-manufacturing
rgmgo
11/11/2020
09:12
Looking in depth at these with their future planned moves their valuation seems significantly at odds compared to their peers. I don't really hold with posters talking about holdings in detail but I will admit to shifting quite a bit around in ISA and Sipp such that MXCT is my largest holding now and I look upon it as the route to a comfortable retirement!🥱 Who knows as a cash generator, maybe even divis one day..
assagai
11/11/2020
08:54
Thanks. Website is a lot better. Agree that the next 12 months should hopefully be very rewarding in these, though planning to hold much longer than that!
adamb1978
11/11/2020
07:09
Hope so - they appear to be getting ready for the next 12 months really. Team appointment, new website etc - spin off should be 2020 as far as we know and nasdaq float next year. Not sure about the next few weeks but Im hoping for a good next 12 months!
nimbo1
11/11/2020
06:56
Thanks Nimbo, more good times ahead fairly soon, we think?
assagai
11/11/2020
06:29
hxxps://maxcyte.com/ Nice new website with good info
nimbo1
06/11/2020
10:38
MXCT mentioned very briefly at 42m54s by Paul Jourdan, in his piworld interview yesterday. Great insight to where he's looking for future winners, and how he views the small cap space. Video: Https://www.piworld.co.uk/2020/11/06/piworld-interview-an-hour-with-paul-jourdan/ Podcast: Https://www.piworld.co.uk/podcasts/
tomps2
05/11/2020
14:18
Interesting trades and share price movement this week. 800k at 400p reported today. If it’s a delayed sell that explains the drop and bounce back. Or was it a delayed buy the MMS accommodated? Also the old classic 1 share trade signal at 8.17 seemed to trigger today’s rise.
acuere
02/11/2020
07:41
AGM results? Discussions? Surely a requirement of AIM?
assagai
22/10/2020
11:06
CRISPR did a webinar on the trial and a presentation. Not a medical person so just trying to understand some of the technical commentary. According to the presentation, the patient who died was a "72-year-old male with relapsed transformed follicular lymphoma following five prior lines of therapy, including autologous stem cell transplant". This patient was the only patient in dose level 4 (DL4) being the highest dosage in the trial. The patient experienced Grade 2 CRS (cytokine release syndrome) at day 5 but this resolved. On day 25, patient was assessed to be a complete responder (ie in complete remission). On day 26, admitted with febrile neutropenia (abnormally low level of neutrophils, a type of white blood cell, accompanied by fever). Confusion and memory loss started at day 28 and further deterioration required intubation (induced coma). Patient initially treated for ICANS (immune effector cell-associated neurotoxicity syndrome) and subsequently determined to have reactivation of HHV-6 (human herpes virus 6) and HHV-6 encephalitis (inflammation of the brain). Patient died at day 52 after family requested withdrawal of care. Seems like the drug worked but that a reactivated viral infection was unable to be overcome. In any event, CRISPR is still enrolling in this trial (and others).
gsbmba99
22/10/2020
10:29
Took a £1000 position & happy to hold see what happens :)
myrmatt
Chat Pages: Latest  14  13  12  11  10  9  8  7  6  5  4  3  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 14:39:29